Suchergebnisse - "Wang, Ke"

PubPharm (99)

1

Competitive coordination assembly of light-degradable gold nanocluster-intercalated metal organic frameworks for photoresponsive drug release

enthalten in: Journal of materials chemistry. B | 2024

von Wang, K. | Zhai, S. | Qin, Y. | +4

2

Three Rounds of Stability-Guided Optimization and Systematical Evaluation of Oncolytic Peptide LTX-315

enthalten in: Journal of medicinal chemistry | 2024

von Fu, X. | Yin, H. | Chen, X. | +8

3

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer : The Phase III DUO-E Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Westin, S. | Moore, K. | Chon, H. | +128

4

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

5

Triple targeting host-guest drug delivery system based on lactose-modified azocalix[4]arene for tumor ablation

enthalten in: Materials horizons | 2023

von Li, J. | Rong, R. | Yang, Y. | +7

6

DROEG : a method for cancer drug response prediction based on omics and essential genes integration

enthalten in: Briefings in bioinformatics | 2023

von Wu, P. | Sun, R. | Fahira, A. | +8

7

Design, synthesis and antitumor activity of potent and safe para-quinone methides derivatives in vitro and in vivo

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Li, P. | Ma, Y. | Wang, K. | +3

8

Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC : A Phase 2b Study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Shi, Y. | Wu, S. | Wang, K. | +46

9

The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma

enthalten in: Cellular oncology (Dordrecht) | 2022

von Shu, W. | Zhu, X. | Wang, K. | +7

10

Novel Hybrids of 3-Substituted Coumarin and Phenylsulfonylfuroxan as Potent Antitumor Agents with Collateral Sensitivity against MCF-7/ADR

enthalten in: Journal of medicinal chemistry | 2022

von Yu, Z. | Li, M. | Wang, K. | +6

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]